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Abstract 
The purpose of this project was to utilize a consumer-directed, care model redesign methodology to develop and evaluate a 
marketing plan for medication therapy management services (MTMS) provided in community pharmacies. This was accomplished 
through a six-step process: (1) application of “design thinking” for eliciting consumer input on redesigning MTMS and marketing 
approaches, (2) exploratory research, (3) focus group analysis, (4) marketing plan development, (5) marketing plan implementation, 
and (6) marketing plan evaluation.  
 
The findings showed that the application of “design thinking” and focus group analysis was useful for creating a consumer-directed 
marketing plan for medication therapy management services (MTMS). Implementation and evaluation of the MTMS Marketing Plan 
revealed that the most successful pharmacies were those that had established business associate agreements with the medical clinics 
closest to their site of practice, including access to electronic health records.  This “virtual electronic presence” of pharmacists in the 
medical care system was highly consistent with the consumer demand we uncovered for a visible relationship between pharmacists, 
physicians and other health care providers.  
 
 
Introduction 
Medication Therapy Management Services (MTMS) have 
been designed to optimize therapeutic outcomes for people 
taking medications. There is evidence for improvement in 
clinical, economic, and humanistic outcomes through this 
service [1-5]. However, a number of barriers to the delivery of 
MTMS have been documented during its implementation 
including: pharmacist training, staffing, management, 
documentation, access to medical records, consumer 
awareness, marketing, provider recognition, and payment for 
services [6-8]. 
 
As barriers to building practices supporting the delivery of 
this service are being addressed [9-13], the practice 
management challenge of marketing MTMS to consumers 
remains. For example, individuals who receive MTMS 
overwhelmingly report: (1) a favorable evaluation of 
pharmacist-provided MTMS, (2) that they would use this 
service again, and (3) that they would recommend it to a 
friend or family member. However, these individuals are rare 
and there is wide variation in how they learned about MTMS 
in the first place [14]. Only a small proportion of consumers 
ever experience MTMS, with most people not even being 
aware that the service is available or what it entails [15-17].   
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Studies show that the current public perception of a 
pharmacist still revolves around the dispensing role, and 
there is very little public knowledge of a pharmacist’s clinical 
role [17-19]. Also, there is evidence of a lack of patient trust 
in the clinical abilities of the pharmacist [17-20]. Law and 
colleagues reported that among Medicare Part D patients, 
only 58% of respondents considered pharmacists to be good 
candidates for providing MTMS [17]. Of this group, 75% 
named their physician as the provider they would visit for 
medication problems [17]. Although there is a general trust in 
pharmacists’ abilities, 70% of those surveyed specified that 
this trust only extends towards prescription dispensing, with 
only 45% trusting their pharmacist for providing advice on 
adverse effects, contraindications, and other “problems” *17+.  
 
Another issue is the public’s low perceived value of MTMS 
which creates a gap between how pharmacists and patients 
view the benefits of this service [17-24]. Research has shown 
that perceived benefits of MTMS were low even among high 
prescription users [17] and may be due to lack of exposure 
and poor understanding of what the service provides [21]. 
Kuhn and colleagues also found that respondents did not 
have a clear understanding of the difference between MTMS 
and prescription counseling [25]. However, after individuals 
receive MTMS, they appreciate it more than those who have 
not [25].  
 
Currently, there is little specific information on creating and 
evaluating a comprehensive MTMS marketing plan. Broad 
suggestions in the literature entail increasing public 
awareness of pharmacists’ clinical abilities, increasing word of 
mouth promotion, addressing patient barriers to MTMS, and 
developing MTMS tailored to patient needs and wants [17, 
20-26]. More specific suggestions focus on collaborating with 
physicians and other health care workers to help them learn 
about the benefits of MTMS and then rely on these clinicians 
to identify patients who they believe would benefit the most 
with a resultant referral to a pharmacist [25]. Another specific 
strategy is to differentiate MTMS from prescription 
counseling so that the public would be willing to utilize and 
pay for MTMS as a “value-added” service *25+.  
 
To help create innovative ideas for the marketing of MTMS, 
we applied “design thinking” to MTMS marketing. Design 
thinking has been described as a process for the practical and 
creative resolution of a problem or issue that looks for a 
specific improved future result [27]. It combines empathy, 
creativity and rationality from the user’s perspective to drive 
business success.  Thus, the purpose of this project was to 
utilize a consumer-directed, care model redesign 
methodology to develop and evaluate a marketing plan for 
medication therapy management services provided in 
community pharmacies. Design Thinking was the general 
approach we used as a first step to elicit consumer/patient 
input on redesigning services and products. With design 
thinking as the starting point, we conducted our study 
through a multiple step process: 
 
 Apply design thinking methods to the marketing of 
MTMS 
 Explore existing resources to help design consumer 
focus groups 
 Complete consumer focus groups using design 
thinking and existing resources as guides 
 Develop the MTMS Marketing Plan 
 Implement the Marketing Plan 
 Evaluate the Marketing Plan 
 
Application of Design Thinking to the Marketing of MTMS 
The use of design thinking methods in this project represents 
a new approach to addressing the MTMS marketing 
challenge.  Application of design thinking methods may be 
ideal for MTMS marketing through an emphasis on out-of-
the-box thinking that rapidly responds to focused client input 
without fear of judgment or criticism.  The creative process is 
based around the "building up" of ideas where there are no 
judgments early on in design thinking thereby eliminating the 
fear of failure and encouraging maximum input and 
participation in generating as many plausible solutions as 
possible [27].  Design thinking methods have been applied in 
healthcare including initiatives supported by the Mayo Clinic 
[28] the Agency for Healthcare Research and Quality [29] and 
the Fairview Health System of Minneapolis –St. Paul [30] to 
name a few. 
 
The design thinking process has seven stages: define, 
research, ideate, prototype, choose, implement, and learn, 
although steps aren't always linear occurring simultaneously 
in an iterative manner [27]. Applied to developing a 
consumer-generated MTMS marketing plan, these stages 
encompassed: 
 
Define:  Agree on the target audience, determine what 
measures will be used to evaluate success. 
Research:  Review the history of existing obstacles and talk to 
end-users to gather the most fruitful ideas for further 
development. 
Ideate:  Identify the needs and motivations of end-users and 
generate as many ideas as possible to serve these identified 
needs. 
Prototype: Expand and refine ideas, create multiple drafts, 
and seek feedback from a diverse group of end-users. 
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Choose:  Review the objective, set aside emotion and 
ownership of ideas, avoid consensus thinking, and select the 
powerful ideas. 
Implement:  Make task descriptions, determine resources, 
and execute the plan. 
Learn:  Gather consumer feedback, discuss improvements, 
collect data and measure success. 
 
Exploration of existing resources to help design consumer 
focus groups 
Enrollment in MTMS for Minnesota 
The first source of information we explored helped us 
understand the level of MTMS utilization in Minnesota, the 
state in which the study was being conducted. Existing 
literature from across the country reveals that consumer 
uptake of MTMS is typically in the 2-10% range of eligible 
patients [3-7, 16, 20, 26, 31-33]. At the time of our study, 
patient enrollment statistics were available for four active 
MTM plans in Minnesota and showed similar enrollment 
patterns ranging from 3 to 10%. 
 
Minnesota Medicaid, Medication Therapy Management Care 
Program 
This statutory MTM program is state-sponsored and serves 
the Medicaid population. State of Minnesota estimates 
showed that approximately 65,000 recipients were eligible 
for enrollment in this program when it was launched in 2006 
[31]. At the time of our study, there were approximately 160 
pharmacists credentialed by the State of Minnesota 
Department of Human Services who had provided MTMS to 
slightly more than 2,000 patients (3% of those eligible at 
program inception).   
 
General Mills MTM Program  
This employer-based program witnessed a patient enrollment 
level of about 3% in the first year. It offered the on-site 
presence of an MTM practitioner at General Mills (employer) 
with paid time off for employees to schedule on-site MTM 
visits. 
 
University of Minnesota UPlan MTM Program  
This program was employer-sponsored and was launched in 
Duluth, Minnesota in 2007 and then throughout the 
University of Minnesota System in 2009.  Data for this 
program showed that 68 beneficiaries, or 6% of eligible 
individuals, enrolled in MTMS in the first 18 months. This 
program offered a value-based beneficiary incentive for 
enrollment (e.g. waived prescription co-payments) [32]. 
 
Minnesota Blue Cross Blue Shield Project  
This program was insurer-sponsored and 285 of 2,834 (10%) 
eligible patients enrolled in MTMS. This program utilized 
seven different recruitment techniques, some of which were 
value-based incentives [5].  
 
This set of information showed that consumer enrollment in 
MTMS was not significantly different than enrollment 
patterns reported in the literature. In Minnesota, 3% 
enrollment was found for two programs that did not have 
value-based incentives for consumers. A program with one 
value-based incentive accomplished a 6% enrollment and 
another program that utilized seven incentives achieved a 
10% enrollment. We viewed this as affirmation that 
Minnesota was typical in that enrollment in MTMS by 
consumers was relatively low but that consumer-directed 
incentives could affect participation in MTMS.  
 
Minnesota Pharmacist Perceptions of MTMS 
The second source of information we explored was from the 
responses of 107 pharmacists attending the Minnesota 
Pharmacists Association (MPhA) – Medication Therapy 
Management Services Annual Symposium held on October 
23, 2009.  This information helped us understand the current 
status of MTMS marketing in Minnesota and the needs of 
practitioners who were providing MTMS. When asked about 
having a marketing plan for MTMS, none of the participants 
reported that they had one. 
 
Discussion at the MPhA meeting showed that marketing 
plans for MTMS need to convince consumers that this 
service: 
 
 saves lives 
 keeps people in their homes longer 
 personalizes / humanizes patient care 
 prevents complications 
 improves health 
 avoids medication misuse 
 saves the patient money 
 gives the patient an advocate 
 saves health care costs at large 
 ensures the safe use of medications 
 fits medications into the patient’s lifestyle 
 
At the MPhA meeting, participants also concurred that there 
are essential steps in marketing MTMS: 
 
 Creating messages which resonate with the target 
clientele; published and refreshed to keep them 
getting noticed. Messages can be posted in the form 
of business cards, brochures, posters, websites, 
newsletters, postcards, video testimonials, podcasts, 
advertising, and results sharing. 
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 Developing a prospect list. Creating a list of all of the 
people you can think of who might be your target 
clients. Then, go through and sort the list prioritizing 
prospects. 
 Meeting with target client prospects. 
 Learning about the prospect, their needs, and their 
obstacles/misperceptions around MTMS. 
 Making it easy for them to give you their business. If 
it is a referral source, give them a ‘prescription pad.’ 
If it is a consumer, give them a business card and 
schedule the first visit. 
 
This information showed that pharmacists who were 
providing MTMS did not have well-developed marketing 
plans, had a desire to promote MTMS to consumers, and 
highlighted the importance of establishing relationships for 
the marketing of MTMS. 
 
Consumer Focus Groups 
With the “design thinking” method serving as a foundation 
and the Minnesota-specific exploratory inquiry providing 
context, the next step of this project was to complete six 
consumer focus groups that would help design the consumer-
generated marketing plan for MTMS. For this project, we 
relied upon community pharmacies that were providing 
MTMS to assist in developing the consumer-generated MTM 
marketing messages and in determining resources needed to 
implement the MTM marketing plan.  A project 
announcement was sent to all community pharmacies 
participating in the Minnesota Pharmacy Practice-Based 
Research Network (MN-Pharmacy PBRN). This research 
network was launched in February of 2008, with the purpose 
of collecting information using a network of pharmacies to 
help address societal and community questions related to the 
medication use process. Such a network serves as a natural 
laboratory and represents a novel way to address societal 
needs related to health and wellness.  
The Minnesota PBRN is a collaborative among the Minnesota 
Pharmacists Association, University of Minnesota, and 
Pharmacist Practitioners 
(http://www.mpha.org/associations/9746/files/PBRN/index.h
tml) and has been designed to serve as a meeting point for 
sharing and generating new ideas that are relevant to the 
interface among the practice of pharmacy, health care, health 
systems, health technologies, communities, and society 
overall. The list of over 300 MN-Pharmacy PBRN pharmacies 
was cross-referenced with the list of over 160 MTMS 
providers recognized in the Minnesota Medicaid Program by 
the Minnesota Department of Human Services and was used 
to identify additional pharmacy sites to receive the project 
announcement. In addition, a general program 
announcement was distributed by the Minnesota 
Pharmacists Association. We sought six pharmacies for this 
study that included chain, independent and clinic community 
pharmacies in both rural and urban settings.  Site selection 
criteria included: 
 Evidence of documented medication therapy 
management services delivered within the practice 
of pharmaceutical care and using the description of 
MTMS contained in official CPT
®
 health reporting 
nomenclature [34]. 
 Evidence of an established practice using the 
Minnesota Department of Human Services (DHS) 
criteria related to the Minnesota Medicaid MTM 
Care Law [31]. 
 Agreement to participate from the pharmacy 
manager, owner, and pharmacist-in-charge. 
 Ability to work with the project team to establish a 
targeted clientele pool for marketing MTMS (using 
both insurance-eligible and non-insurance eligible 
individuals). 
 Ability to recruit 8-12 consumers to participate in a 
focus group session to formulate MTMS marketing 
messages (using both individuals who have received 
MTMS and those who have not received MTMS). 
 Access to a location to convene the focus group 
session. 
 
A total of 10 Minnesota pharmacies meeting all of the 
inclusion criteria indicated a willingness to participate in the 
project within our stated time frame. From these, six 
pharmacies were selected for participation in the project 
based on size, type and geographic distribution. Pharmacies 
agreeing to participate in this project were expected to 
benefit from the development of an MTMS marketing plan 
for use in their pharmacy, and also received a project 
honorarium of $500.00 for their participation.  
 
Consumers were recruited to participate in focus group 
sessions by project pharmacies.  Each site was asked to 
identify a mix of individuals who were both receiving MTM 
services as well as individuals who had not received MTM 
services who might be expected to benefit from the service 
(based on their medication experiences).  Each project 
pharmacy was asked to sign-up 12-15 consumers for a two-
hour focus group session, and to contact each participant 1-2 
days before the meeting to confirm participation.  Consumers 
participating in the MTMS focus group meeting received a 
$25 gift card for household goods.  The Minnesota 
Pharmacists Association, as steward of the MN-Pharmacy 
PBRN, served as project administrator for distribution of 
honoraria to pharmacies and incentive gift cards to 
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consumers. Consumers were selected based upon 
pharmacists’ relationship with each person and their 
understanding of each person’s medication experiences. The 
goal for focus group composition was to include consumers 
who: (1) represented diverse opinions about medication use, 
(2) were open to sharing their opinions in respectful way, (3) 
had a diversity of medication experiences that would inform 
our study, and (4) could be counted upon to attend the focus 
group.  
 
Project pharmacies were asked to find a meeting location and 
all focus group sessions were conducted in the evening at a 
variety of community locations.  Sites were also asked to 
provide light refreshments and snacks to the extent possible. 
Although site pharmacists could greet consumers prior to the 
focus group meetings, they were not permitted to be present 
during focus group proceedings.  The six focus group sessions 
were held November 8, 2010 (Albert Lea), December 1, 2010 
(Rochester), December 2, 2010 (Anoka), January 18, 2011 (St. 
Louis Park), January 27, 2011 (St. Paul), and February 10, 
2011 (Brainerd). 
 
A skilled focus group moderator from the “markit” marketing 
company of Rochester, MN was utilized to convene the focus 
group meetings.  One additional project team member was 
present during each focus group session to assist the 
moderator.  The moderator drafted a discussion guide prior 
to each focus group session to facilitate discussion based on 
input from the project team.  Participants were welcomed by 
the moderator who first explained the purpose of the focus 
group meeting and then reviewed standard informed consent 
with the group. Appendix A contains the Moderator 
Discussion Guide and Appendix B describes the Informed 
Consent process used in this project.  Focus group 
participants were also informed that the session was being 
recorded using a digital recorder for transcription purposes 
and that all transcripts would be destroyed after analysis.  
The Tybee Types transcription service of Savannah, Georgia 
was used to transcribe digital recordings. 
 
An important aspect of the focus group session was 
permitting participants to provide perspectives on their 
current health care delivery concerns and drug-related needs 
prior to establishing baseline expectations for a MTMS 
encounter.  The concept of MTMS was then reviewed with 
the participants after allowing sufficient time for describing 
their health care concerns and drug-related needs.  The 
centerpiece for establishing MTM service expectations [35, 
36] was an 8-minute DVD developed by the Pharmacist 
Services Technical Advisory Coalition through a previous 
Community Pharmacy Foundation grant [37].  After viewing 
the MTMS video, participants were asked to provide general 
comments about the service, express ideas of how it could 
improve their health, and to provide solutions on how to best 
generate awareness for MTMS. 
 
There were 61 consumers who participated in the six MTM 
focus group sessions (range = 8 – 13 consumers per focus 
group session).  Approximately 60% of focus group 
participants were female with an age range of 30-90 years of 
age.   
 
Development of the MTMS Marketing Plan using Focus 
Group Findings  
Focus group session transcripts were analyzed to discern key 
marketing messages and to reveal recurring themes and 
patterns.  One of the tools for identifying recurring themes 
and patterns employed a computational linguistics technique 
that seeks patterns of semantic relatedness [38-41].  A 
subcontractor agreement was established with the University 
of Minnesota – Center for Clinical and Cognitive 
Neuropharmacology (CCCN) to assist in this task.  Faculty with 
expertise in integrating computational approaches to the 
assessment of cognition through speech and language use 
applied computational linguistics [38-41] in their analysis of 
the focus group transcripts. This analysis produced a 
hierarchy of MTM service level expectations and key MTM 
marketing messages. 
 
In addition, a thematic analysis of the focus group transcripts 
was conducted by the “markit” marketing company of 
Rochester, MN. Theme extraction was based on convergence 
and external divergence; that is, identified themes were 
internally consistent but distinct from one another [42]. The 
participant statements referring to a particular theme were 
grouped and further explored and compared with initial key 
ideas [43]. Once the initial analysis was carried out, the 
interpretations were discussed among the study investigators 
who conducted the thematic analysis. Agreement was 
negotiated as a valid interpretation of the text and this 
discussion was driven by the study objectives as well as 
consistency of emergent themes.  When the final set of 
analyses was compared, all investigators agreed upon major 
themes.  
 
Triangulation, done by using multiple analysts and multiple 
methods, also provided a quality check on selective 
perception and blind interpretive bias that could occur 
through a single person doing all of the analysis or through 
employment of a single method [44]. For triangulation, 
findings from the thematic analysis were combined with 
findings from the computational linguistics analysis. This 
information was fed back to the project team and to the 
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project sites for review and to confirm the recurring themes 
and messages.   
 
The application of computational linguistics resulted in a 
matrix of content analysis categories.  The three most 
dominant content analysis categories of the focus group 
transcript analysis were:  
 
1.)  Team-based care (24% of focus group comments), 
2.)  Quality of information source (15% of focus group 
comments), 
3.)  Relationship/trust (14% of focus group comments). 
 
These findings were consistent with the thematic analysis. 
The most dominant message of “team-based care” emerging 
from focus group participants was manifest in the recurring 
comment that MTM services need to be “visibly” integrated 
with care delivered by physicians and other health care 
providers (team-based content analysis).  The content 
analysis categories of “quality information source” and 
“relationship/trust,” were manifest in focus group 
observations in that communications (letters and phone calls) 
about MTM services were welcome from the pharmacist, 
physician or other health team members.  Although 
consumers expressed a desire to know whether or not MTMS 
was a covered benefit in their health plan, communications 
from the insurance company directing them into MTM were 
viewed as undesirable and perceived as money-making 
schemes. 
 
Key messages, or MTMS attributes, that resonated with 
consumers influencing their health care decisions and 
behaviors were that MTM services would optimize the safe 
and effective use of medications, improve treatment 
outcomes, and improve quality of life.  There was 
overwhelming support for MTM services provided at the level 
described in the 8-minute CPF MTM video, and all but two 
participants indicated a willingness to pay for MTM services 
(range = $25 - $125/encounter).   
 
Findings from the six focus group sessions were similar. By 
the sixth session, saturation had been reached in that no new 
information was being gleaned from additional sessions. A 
summary of findings from the focus groups is contained in 
Appendix C. The findings from the focus groups were 
combined and used to develop a single MTMS Marketing 
Plan. This plan is presented in Appendix D.  
 
Marketing Plan Implementation 
Project sites were asked to implement the MTM marketing 
plan to the fullest extent possible during the six-month study 
period of March 1, 2011 – September 1, 2011.  
Implementation support was provided to project sites by the 
“markit” company (Rochester, MN) on a regular basis and 
faculty on the project team contacted sites on a monthly 
basis to discuss progress.  Based on the dominant focus group 
marketing message (team-based care), a two-page MTM Fact 
Sheet was developed to assist sites with physician 
collaboration (see Appendix E). 
 
The MTM marketing plan was implemented at five out of the 
six project pharmacies.  One rural site was unable to 
implement the marketing plan due to the fact one of their 
pharmacists moved from the community and they were 
unable to hire another pharmacist during the project period. 
The five project pharmacies implementing the MTM 
marketing plan over the six-month study period are listed in 
alphabetical order below: 
 
 Cub Pharmacy, St. Louis Park, MN 
 Goodrich Pharmacy, Anoka, MN 
 GuidePoint Pharmacy, Brainerd, MN 
 Mayo Clinic-Baldwin Pharmacy, Rochester, MN 
 Walgreen’s Pharmacy, St. Paul, MN  
 
No additional project funds above the $500 honorarium were 
available for sites to implement the MTM marketing plan. 
Project sites did receive feedback from the project team in 
terms of articulating their target market, presenting the MTM 
service concept to physicians and health team members, 
recruiting patients, and in developing marketing materials 
and tools.  However, each project site was expected to 
produce and distribute its own MTM marketing materials.  
 
The target market of prospective MTMS patients at project 
sites was established by personnel in each pharmacy based 
on both insurance-eligible MTMS recipients and targeted 
patients who did not have MTMS as a health insurance 
benefit. Each pharmacy determined its own target market 
based upon its own experiences, the marketing plan 
(Appendix D), and consultation with study personnel. Success 
in this project was described a-priori as an increase of at least 
5-10% in new patient MTMS appointments above each 
pharmacy’s anticipated baseline new patient appointment 
rate over a six-month period. 
 
Marketing Plan Evaluation 
The two key measurement criteria applied in this project 
were: (1) the percentage increase in new MTM patient 
appointments above anticipated six-month baseline and (2) 
estimated resources needed for full implementation of the 
MTM marketing plan in each project pharmacy. In addition, 
pharmacists were asked to provide their insights and 
reflections regarding implementation of the marketing plan. 
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Increase in new MTM patient appointments above baseline 
A baseline rate of new patient appointments for each 
pharmacy was calculated by dividing the number of new 
patient appointments by the length of time that MTM 
services were being delivered before the implementation 
period. For instance, if a site had provided MTM services to 
165 patients over a two-year period their baseline new 
patient appointment rate would be 0.226 new patient 
appointments/day.  This baseline appointment rate was then 
compared to the rate of new patient appointments after 
implementing the MTM Marketing Plan over the six-month 
study period. 
 
The table below summarizes new patient appointments per 
day pre-, and post-implementation of the MTM Marketing 
Plan arranged according to % change over baseline without 
identifying individual project sites. 
 
 
Sites arranged by greatest 
% change over 6-months 
 
 
Baseline rate/day
a
 
and (Total) 
 
(pre-period data) 
 
Actual rate/day
b
 
and (Total) 
 
(post-period data) 
 
% Change 
 
 
 
Greatest change over baseline 
Second greatest change 
Third greatest change 
Fourth greatest change 
Fifth greatest change 
 
Totals 
 
0.175/d (32) 
0.226/d (41) 
0.048/d  (9) 
0.329/d (60) 
0.138/d (25) 
 
0.915/d 
(167 new patients) 
 
0.617/d (111) 
0.578/d (104) 
0.067/d  (12) 
0.383/d  (69) 
0.106/d  (19) 
 
1.751/d 
(315 new patients) 
 
(+) 248% 
(+) 156% 
(+)  40% 
(+)  16% 
(-)  23% 
 
(+) 91% 
(152 above baseline) 
 
a 
Expected number of new patients based upon baseline rate at start of implementation period. 
b
 Actual number of new patients and new patient rate during implementation period. 
 
There were 315 new patient appointments (495 total MTM 
encounters) during the six-month study period in these five 
sites. This represents a 91% (152 patient) increase in new 
MTMS patient appointments over the pre-implementation 
period baseline. A baseline rate of new patient appointments 
for each pharmacy was calculated by dividing the number of 
new patient appointments by the length of time that MTM 
services were being delivered.  The baseline new patient 
appointment rate among the five pharmacies prior to 
implementation of the MTM marketing plan was 0.915 new 
patient appointments per day.  During the six-month 
implementation period the new patient appointment rate 
among the five pharmacies was 1.75 new patient 
appointments per day.   
 
It should be noted that the “fifth greatest change” pharmacy 
experienced the departure of their primary MTMS pharmacist 
and project point-person during the implementation period. 
This pharmacy was unable to replace that pharmacist and 
was not able to fully implement the MTMS marketing plan. 
 
Financial Estimates for Full Marketing Plan Implement 
Project sites were asked to provide estimates of the 
resources needed to fully implement the MTM Marketing 
Plan at a level that would achieve a desirable level in each 
pharmacy.  Financial estimates were categorized as either 
personnel or non-personnel expenses.  Personnel expenses 
included salaries and benefits of pharmacists, pharmacy 
technicians, and supportive personnel needed to contact 
patients, meet with physicians and other health 
professionals, develop the marketing strategy, assemble 
promotional materials, and other tasks related to 
implementing the marketing plan.  Non-personnel expenses 
included materials, radio and newspaper advertising costs, 
printing and mailing costs, and other promotional expenses. 
 
The combined estimates of marketing expenses that would 
be needed to fully implement the MTM Marketing Plan 
developed in this project at levels determined to be desirable 
by each pharmacy was $2,749 per pharmacy ($13,745 for all 
five).  Most of the project sites estimated personnel costs 
associated with full implementation of the MTM Marketing 
Plan slightly higher than non-personnel expenses.  The 
cumulative marketing plan estimates of personnel expenses 
was $1,410 per pharmacy ($7,050 for all five), with non-
personnel expenses of  $1,339 per pharmacy ($6,695 for all 
five). 
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There was no discernable association between “% change 
over baseline” and personnel costs reported. However, 
estimated non-personnel costs were higher for the top three 
“change” pharmacies ($1,500, $1,395, and $1,500, 
respectively) compared with the “fourth greatest change” 
and “fifth greatest change” pharmacies ($1,000 and $1,000).  
  
Pharmacist Reflections on Project Participation 
Pharmacists at each pharmacy were asked to provide their 
reflections on what they liked best about participating in this 
project, and what they think could have been improved in 
this project.  All of the sites were thankful for the focus group 
sessions that provided insight and information about what 
patients valued and their perceptions of MTM services.  The 
opportunity to develop a formal MTM services marketing 
plan and to establish a target market through the efforts of a 
marketing company with experience in pharmacy and health 
care was also viewed as a benefit.  The benefits of 
participating in this project were succinctly summarized by 
the following comments from one of the project pharmacists: 
 
“The most helpful information we received came from the 
patient focus groups, which gave us information about what 
patients thought were the most important things about 
MTMS.”  
 
“The most success we had in our personal marketing 
approach was going right to the physicians and getting them 
to promote our services.  Simply by convincing them that 
MTM is an important part of care.” 
 
Areas of improvement related to the need for more resources 
to develop physician relationships and to fully implement the 
marketing plan.  Project pharmacists also expressed 
challenges related to explaining MTM services to patients.  
Due to the fact that most patients were unaware of their 
MTMS insurance benefit, pharmacists spent a great deal of 
time and effort explaining MTM to patients.  One project 
pharmacist summed up this challenge by commenting: 
 
“Because the patient was not informed of MTM and their 
benefits from their insurance company or from their physician 
they feel we are solicitors and thus are skeptical of the MTM 
service.”    
 
Discussion  
Limitations 
Before the findings are discussed, study limitations should be 
acknowledged. First, all participants volunteered for the focus 
groups and therefore may have been more knowledgeable 
than non-participants with respect to the topic. However, the 
emphasis in focus group research is to select people who are 
conversant with a given phenomenon, so this is not 
necessarily a bias. Second, there may have been some 
interviewer bias due to experience and training. However, 
every effort was made to control this by maintaining a neutral 
position and intervening only to facilitate smooth discussion. 
Third, statements could be categorized in more than one 
way. Hence, themes identified cannot be regarded as 
exclusive or exhaustive. Fourth, the focus groups were held in 
six geographic areas. Individuals from different regions may 
not share the perceptions and views identified here. Fifth, the 
implementation study was conducted in only five 
communities located within Minnesota. Other geographic 
regions may not have the same experiences as the ones 
reported in this study. Sixth, a before-and-after without 
control group quasi-experimental design was used for 
evaluation. Without a control group, it is difficult to establish 
cause-effect for the intervention being studied. However, the 
before-and-after design typically is most useful for 
demonstrating the immediate impacts of short-term 
programs such as the one we investigated. Finally, the five 
study-pharmacies had varying levels of success in the 
implementation of the marketing plan developed in this 
project. The pharmacy with the least success (determined by 
change in new patient appointments per day pre- and post-
implementation of the marketing plan) also was the 
pharmacy that was least able to implement the marketing 
plan (determined by the departure of its MTMS point-person 
and its inability to fully implement the marketing plan). While 
this provides some credibility for our findings, there may be 
other factors that are important for marketing MTMS that are 
beyond the scope of this study. 
 
Study Implications 
With these limitations in mind, we suggest that the 
application of “design thinking” *27+ was useful for creating a 
consumer-directed marketing plan for medication therapy 
management services (MTMS). The use of patient panels and 
patient advisory groups is becoming a central component of 
redesigned health care delivery systems [28-30]. Asking the 
end-user to provide direct input into the way health care 
should be delivered is a process that has been successful in 
many industries [27]. Pharmacists can use the consumer 
focus group tools developed in this project to gather 
information and gain support for the delivery of MTM 
services.  
 
Through the focus groups, we learned that marketing for 
MTMS should maximize the messages of: (1) what MTM 
services are and why they are important, (2) MTMS is part of 
team-based care for which a patient’s physician is considered 
as the primary authority and the patient’s pharmacist is a 
trusted expert or advisor on medications, (3) the pharmacist 
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is the highest quality practitioner for providing MTMS, and (4) 
relationship / trust among providers, patients, and payers of 
health care so that MTM services are not viewed as a ruse for 
making money at the expense of the patient.  
 
Implementation and evaluation of the MTMS Marketing Plan 
revealed that the plan we developed was successful for 
increasing new MTM appointments for some, but not all, of 
the study pharmacies. The most successful pharmacies were 
those that had a “visible” relationship between the 
pharmacist and the physician and had integrated MTM 
services into health care delivery.  An important observation 
is that the two most successful project pharmacies had 
established business associate agreements with the medical 
clinics closest to their site of practice, including access to 
electronic health records.  This “virtual electronic presence” 
of pharmacists in the medical care system is highly consistent 
with the consumer demand for a visible relationship between 
pharmacists, physicians and other health care providers. 
 
Findings from the evaluation also provided a glimpse of the 
resources that may be needed to implement an MTM 
marketing plan necessary to grow MTM services to desired 
levels. Our study revealed that project sites increased the 
number of new patient appointments by an average of 91% 
above baseline and estimated that they would need an 
average investment of $2,749 over a six month period to fully 
implement the MTM marketing plan. It is beyond the scope 
of this study to conduct break-even analysis and long-term 
return-on-investment analysis. However, we propose that our 
findings are consistent with previously reported research [9-
13] and suggest that initial costs would be expected to 
decrease over time as the practice supporting the delivery of 
MTM services expands. It is interesting to note that the most 
successful pharmacies reported higher non-personnel costs 
for implementing the marketing plan. We propose that this 
would be a fruitful area for future research. Another area for 
future research would be to compute the cost per new 
patient or additional new patient enrolled in order to 
determine how much it would cost in terms of marketing 
materials to attract additional patients. The number of new 
patients might increase without a proportional increase in 
cost of marketing over time. 
 
The results of this project can have immediate application in 
national efforts to redesign health care delivery. The 
appropriate, effective and safe use of medications is essential 
to achieving the three-part national aim of (1) better care for 
individuals, (2) improved health for populations, and (3) 
decreased per capita expenditures.  The relevance of this 
project pertains to engaging consumers as activated patients 
*45+ and in efforts to integrate pharmacists’ work in health 
teams *46+. Integrating pharmacists’ MTM services into 
patient-centered health homes not only helps patients 
improve their own healthcare, but also is important in 
defining the value equation, measuring quality, and 
redesigning care systems [47], accountable care organizations 
[48], and pay-for-value [49].  
 
It is also important to note that key MTM messages 
resonating with consumers are closely tied to service level 
expectations for the delivery of MTMS [35, 36].  Emphasis on 
descriptions contained in official health reporting 
nomenclature [34] coupled with the rich narrative description 
of MTMS provided in the 8-minute MTM DVD video that was 
used in this study [37] established a clear consumer 
understanding of what should and will happen during an 
MTM service encounter. Providing MTM services at a 
consistent level recognized by society is an essential aspect of 
consumers’ perceptions of service quality predicting intended 
behaviors in the dynamic process model of service quality 
[35, 36].  Pharmacists seeking to build practices that support 
the delivery of MTM services can expect to benefit from 
employing a complete and consistent patient care processes 
[50] and from distributing regular and compatible 
promotional messages to educate consumers and health 
professionals [37].    
 
Conclusions 
The purpose of this project was to utilize a consumer-
directed, care model redesign methodology to develop and 
evaluate a marketing plan for medication therapy 
management services provided in community pharmacies. 
The findings showed that the application of “design thinking” 
was useful for creating a consumer-directed marketing plan 
for medication therapy management services (MTMS).  
Implementation and evaluation of the MTMS Marketing Plan 
revealed that the most successful pharmacies were those 
that had established business associate agreements with the 
medical clinics closest to their site of practice, including 
access to electronic health records.  This “virtual electronic 
presence” of pharmacists in the medical care system was 
highly consistent with the consumer demand we uncovered 
for a visible relationship between pharmacists, physicians and 
other health care providers.  
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Appendix A 
Medication Therapy Management Discussion Guide 
 
I. Introduction  (10 minutes) 
a. Format for the evening 
b. Expectations for participation – go over Participation Consent Information 
c. Tape recording of the session – speak slowly and articulate 
d. Housekeeping  
e. Roundtable introductions – give us 5 words that describe you 
 
II. Perspective on their current drug therapy program (25 minutes) 
a. What do you think is the role of the physician? 
b. What do you think is the role of the pharmacist?  Could he/she do more for you?  If so, what would that be? 
c. Issues they have with the current system (how is it working for you?) 
d. If you could make it better, what would it look like? 
e. If it doesn’t come up…probe for issues with drug interactions and how their issues were resolved.  Did they find 
that acceptable? 
 
III. Reactions to the concept of MTM (10 minutes) 
a. When I say the words Medication Therapy Management, what thoughts come into your mind about what that 
might be? 
b. Does it sound like something that might address the issues you have with your current program? 
c. How would you go about learning more about it? 
 
IV. View the video with discussion (40 minutes) 
a. I’m going to introduce you to a relatively new concept called Medication Therapy Management.  We’ll watch 
this 8 minute video and then discuss your reactions to it. (play video) 
b. What are your initial reactions to the video? 
c. After watching the video, what is your understanding of what MTM is?  Is that valuable to you? 
d. What do you think the benefits are of MTM? 
e. What are some of the key points that stuck with you? 
f. What are the lingering questions you have about this program? 
 
V. Reactions to MTM (15 minutes) 
a. Now that you know something about MTM, what are your reactions to the name?  Like it, don’t like it?  Why? 
b. Does it adequately describe what this program is?  Why do you say that? 
c. If this service were not covered by insurance, would you pay for it out of your own pocket?  Why? 
 
VI. How to reach our audience (15 minutes) 
a. What is the best way to get the MTM message across to the people we are trying to reach? 
b. What is the responsibility of the physician? 
c. What is the responsibility of the pharmacist? 
d. If you saw advertising in magazines or the TV would that make it more credible to you? 
 
VII. Thank participants for their time (5 minutes) 
a. Fill out demographics sheet  
b. Give them their debit cards 
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Appendix B 
Participation Consent Information – Medication Therapy Management Focus Group 
 
This document provides information to participate in the project titled, “Evaluation of a Consumer-generated Medication Therapy 
Management Marketing Plan.”  The markit® marketing firm of Rochester, MN is facilitating this focus group session through a 
contract with the University of Minnesota College of Pharmacy.  This project is funded by the Community Pharmacy Foundation.    
 
The following key points for participating in this project include: 
 
1. The reason for the project. The Community Pharmacy Foundation has awarded funding in the form of a grant to create a 
medication therapy management marketing plan that will provide guidance to my pharmacists to enhance these services within my 
pharmacy, or provide helpful information to assist with the implementation of these programs for my pharmacy’s customers.  The 
benefit to consumers is greater confidence that medications are being used properly to get the best outcomes possible. 
 
2. The project procedures are as follows:  Volunteers have been invited by their pharmacist to join a focus group of about 8-12 
participants.  The focus group session is expected to last two hours.    During the focus group, participants will be asked about 
current awareness and perceptions of Medication Therapy Management Services (MTMS).  Potential marketing messages will be 
tested for their ability to communicate key aspects of the program.  The focus group session may be audio recorded, although any 
audio tapes will be destroyed after they are transcribed. 
 
3.  Participation will be confidential and will not be released in any individually identifiable form.  Your pharmacist has asked 
you to participate in this focus group session.  Individuals at the University of Minnesota College of Pharmacy will not have access to 
any information that could link individuals to the care they receive or to participation in this focus group session.  Any project 
reports that may be published will only describe the aggregated results of all individuals. 
 
Participation in this project is entirely voluntary.  In addition, individuals can withdraw from participation at any time without 
affecting your relationship with your pharmacist or the University of Minnesota.   A small gift card will be provided to you in 
appreciation of your participation at the conclusion of the focus group session. 
 
It is understood that questions may be asked at any time by contacting my pharmacist or by contacting markit® located at 320 South 
Broadway, Rochester, MN 55904, or by calling 507-529 9000.  Questions can also be directed to personnel at the University of 
Minnesota by contacting Brian Isetts (at 612-624-2140) or Jon Schommer (at 612-626-9915). 
 
Thank you. 
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Appendix C 
Focus Group Findings 
 
Methodology 
•    Conducted 6 focus groups –  
Cub Foods, St. Louis Park, MN  
Goodrich Pharmacy, Anoka, MN  
  Guidepoint Pharmacy, Brainerd, MN 
   Mayo Clinic Pharmacy, Rochester, MN  
   Sterling Drug, Albert Lea, MN 
   Walgreens, St. Paul, MN 
• Participants were recruited by the individual pharmacies based on their eligibility for participation. 
• Participants attended a 2 hour group discussion on MTM to understand their attitudes, perceptions, beliefs and 
behaviors concerning MTM. 
• A DVD was shown half way through the group time that explained MTMS. 
 
Current Drug Therapy Program 
Role of the Physician 
•    Considered to be the authority on what medications are best for the patient. 
•    Understand what the patient is taking. 
•    Understand the side effects of medications they prescribe, and how different medications interact with one 
another. 
•    Provide education to the patient on medications. 
•    Follow up to insure patient effectiveness. 
•     This view changes depending on the patient’s relationship with their doctor. 
•    The more trust there is in the relationship, the more highly regarded the advice. 
 
Current Drug Therapy Program 
Role of the Pharmacist 
•    Viewed as a “coach” or “advisor” on medications. 
•    Monitor medications, patient safety. 
•    Answer questions patient may have. 
•    Tell patient what to expect. 
•    Suggest alternatives. 
•    Help address cost and insurance issues. 
•    Provide recommendations on OTC products. 
•    Viewed as more available than their doctor, and will spend more time with the patient. 
•    Viewed as a part of the patient’s care team, without the intimate knowledge of the patient that the doctor has.  
 
Current Drug Therapy Program 
Issues with their current program 
•    Multiple concerns exist regarding the use of medications. 
•    Timing of administration of various medications, adherence to dispensing of medications. 
•    Overdosing on medications. 
•    Mail order programs, no pharmacist relationship – no one to talk to when needed. 
•    Notification when medications change in size, dosage, shape. 
•    Most had not experienced a negative drug interaction and were not overly concerned about it.  There was a direct  
correlation between satisfaction with physician and concern over issues with their medications. 
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Reactions to MTM (prior to viewing video) 
Awareness of what MTM is 
•    There is general confusion about what MTM is, though not surprising given the newness of this concept to the market. 
•    Respondents reported that MTM ranged from a pill box to an integrated system of managing the patient’s 
medication needs. 
•    They did feel this was something that a patient would have a greater need for the more medications used. 
•    Overall concern regarding how to handle information that might be contradictory to their physician. 
 
Reactions to MTM (following the viewing of the video) 
Understanding of the concept 
•    Participants were able to grasp the concept of what MTM is from the video. 
•    Attitudes towards MTM were very positive, high value was placed on the pharmacist being a member of the healthcare 
team. 
•    Respondents felt insurance companies should cover cost of MTM, the benefit to them is reduced medication costs.  
•    Service is more accepted with the support of the physician (the physician continues to play the lead role in the healthcare 
team). 
 
Reactions to MTM (following the viewing of the video) 
Participants rank ordered the benefits of MTM, from most important to least important, as follows: 
•    Optimizes the safe and effective use of medications. 
•    Improves my treatment outcomes. 
•    Improves my quality of life. 
•    Gives me confidence that I am doing the right things for my best health. 
•    Promotes collaborations between pharmacists, physicians and patients. 
•    Allows me to manage my medications, they don’t manage me. 
•    Provides me with a written record of my conditions and medications. 
 
Reactions to MTM (following the viewing of the video) 
Insurance related issues 
•    Participants felt MTM should be covered by insurance. 
•    Structure should include an initial visit, with subsequent visits dependent upon changes in medication or health status. 
•    If insurance did not cover MTM visits, participants felt they would use the service only under more severe circumstances. 
•    While most had no idea what the service was worth, they were able to put a value on the service (median value of $50 
per hour for the service encounter). 
•    No one knew that MTM was a benefit of the Medicare Part D Drug Program as a comprehensive medication review for 
beneficiaries with complex drug-related needs. 
 
Reactions to MTM (following the viewing of the video) 
Views on the name – Medication Therapy Management 
•    Some participants felt the term “therapy” was confusing and might not be necessary. 
•    Participants do not think that their medications are a form of therapy, they think of therapy as in “physical therapy.” 
•    Participants liked the term “medication management” better and felt it was more descriptive of the concept. 
 
Reactions to MTM (following the viewing of the video) 
How to reach the target audience 
•    Participants want to know that their doctor is in support of them participating in an MTM program. 
•    They need to know that members of their healthcare team are working together for their benefit. 
•    They would attend an MTM session at their doctor’s recommendation, some said though that they thought their doctor  
           would not agree to it. 
•    Upon doctor’s recommendation they would attend if contacted by the pharmacist, either by a face-to-face conversation 
   or a phone call from the pharmacist. 
•    Letters or calls from anyone other than the physician or pharmacist would not be received as well. 
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Appendix D 
Medication Therapy Management Services  (MTMS) Marketing Plan 
University of Minnesota – College of Pharmacy 
February 15, 2011 
 
What is a marketing plan? 
 
A marketing plan is a document that identifies the goals to be achieved through the marketing plan, the audience that the author 
desires to reach, the issues getting in the way of achieving the goals, and the strategies and tactics to be implemented that will 
address the issues to achieve the goals. 
 
Six Month Goals 
 
 Increase enrollment of MTM eligible patients by at least 5-10%. 
 Acquire an understanding of the most successful approach to attract new MTM patients. 
 Educate physicians on the enhanced role the pharmacist can play in the health of their patient. 
 Educate patients on the valuable service that is available to them to optimize the benefits of their medications.  
 
Target Audience – Patricia and John 
 
Patricia and John are a retired couple.  He was an electrician and she was a school teacher.  John has diabetes and high blood 
pressure.  Patricia has high cholesterol and has had one heart attack.  Both take multiple medications for their conditions.  They visit 
their doctors regularly and are proactive in managing their medical conditions. 
 
Patricia and John have a modest income, but do enjoy traveling when they can.  They also like to keep active by volunteering, and 
visiting with friends and family.  They view themselves as hard-working, caring, compassionate people who enjoy being around 
others.  
 
Patricia and John are not familiar with what MTM is, but do have insurance that covers it.  They feel the role of their pharmacist is to 
be an extra set of expert eyes to help manage their medication therapy.  The pharmacist is a person they have a relationship with.  
They trust them and feel they can go to them with questions.     
 
Issues 
 Getting physicians on board with the concept is critical to the program’s success. 
 Physicians may view this program as a threat to their role with patients. 
 The roles of the physician and pharmacist need to be clearly defined and understood as a benefit to the physician. 
 A system of communication needs to be developed to share pharmacist recommendations that is not driven by the patient. 
 Increasing stakeholder awareness of the pharmacists’ clinical abilities is needed. 
 Differentiating prescription counseling from MTM, people have no concept of what to expect from an MTM session. 
 There is a huge educational component to this program. 
o To physicians  
 value of working together with the pharmacist for the benefit of the patient 
 role that the pharmacist is capable of playing 
o To consumers 
 benefits of the program 
 support of physicians  
 coverage by Medicare Part D 
 role that the pharmacist is capable of playing 
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Key Messages 
 
Key messages are important in the communication of the benefits of the program.  Messages have to meet three criteria.  They must 
be relevant, believable and distinctive.  The following are the top three messages identified by focus group participants as meeting 
the criteria.  Use of these messages in the verbal and written language you use to describe MTM will resonate with your audience. 
 
Key messages are: 
 Optimizes the safe and effective use of medications 
 Improves my treatment outcomes 
 Improves my quality of life 
 
Strategies and Tactics 
 
Step 1 - Product 
 
One of the aspects of a successful program is a visible relationship between the physician and the pharmacist.  The patient has a 
strong belief that the physician is the leader of the team.  The pharmacist plays more of a specialist role. 
 
An MTM meeting includes a review of the medication list and of medical issues, discussion of drug related issues/concerns, and 
recommendations for change.  MTM consists of an initial visit.  Subsequent visits occur when the patient has a change in their 
medical situation or when another medication is added to their list. 
 
“Medication Therapy Management” is not an appealing name.  The recommendation is to drop “Therapy.”   
 
1. Determine a name for your program – Medication Therapy Management, Medication Management, Medication Check-up 
are a few possible names. 
2. Establish protocols for the patient meeting and physician follow-up. 
 Document these protocols as they will be valuable in talking with physicians and other interested parties. 
3. Establish a tickler system that prompts you when an MTM patient has a new medication (for follow-up MTM sessions) 
 When prompted, contact the patient and suggest a date and time to get together for a review. 
 
Step 2 - Price 
 
Based on the research conducted, it is not very likely that consumers will pay for this service out of their pocket.  Therefore, the 
focus should be on recruiting patients that have insurance coverage for the service.  Cost for MTM services should be calculated in 
accordance with the guidelines provided by the individual companies.   
 
1. Investigate which insurance companies provide reimbursement for MTM consultations. 
2. Identify, based on the program, what you will charge for the consultation. 
 
Step 3 - Place 
 
From the consumers point of view, where the MTM session is conducted is not a particular issue.  If it makes sense, consultations 
could be done in the patient’s doctor’s office.  Or, it could be done in the pharmacy.  What is required is a private, enclosed space.   
 
1. Define a designated space to conduct MTM sessions. 
2. Identify patients from your database that would be good candidates for MTM.  They are: 
 Taking multiple medications 
 Have insurance coverage for MTM visits 
 Have a good working relationship with your pharmacy 
 Have a physician that you feel is already, or would be, supportive of the program 
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Step 4 - Promotion 
 
Awareness for what an MTM program is very low.  In the initial stages of a program launch, you will need to educate your audience.  
A critical factor is the visible relationship between pharmacist and physician.  Getting the support of the physician with their patients 
will increase the participation rate.  
 
Tactics for a new MTM program: 
 
1. Create a brochure or information flier as a leave behind piece when talking with physicians about the program. The 
piece could also be used by physicians to recommend MTM to patients.  
 Benefits of MTM 
 How MTM is different than pharmacist consultation 
 What the process is 
2. Work with local physicians to get support for conducting MTM sessions with their patients whom you have identified. 
 Conduct in-service sessions to educate doctors on the benefit of MTM for them, and protocols for patient 
meetings and physician follow-up 
3. Schedule follow-up meetings with physicians that attend the in-service to talk with them about specific patients that 
could benefit from an MTM consultation. 
 Determine who will contact the patient to schedule a meeting. 
 Face-to-face or phone call contact from either the pharmacist or physician is best.  It sends the message that MTM 
is important 
4. If a patient is on your target list, talk to them when they are in the pharmacy to pick up a prescription.  
 
Assuming you have the support of local physicians, the next level of marketing can be focused on enhancing awareness directly with 
patients.   
 
Tactics to enhance an existing MTM program: 
 
1. Increase awareness of what MTM is with local service clubs, senior centers, or associations whose members fit the 
target audience profile 
 Create a short 15 minute presentation that talks about what MTM is, the benefits of MTM, what an MTM 
consultation consists of, and some examples of how it has helped your patients. Utilize the MTM DVD that has 
been provided with this plan as an additional source of information for your audience. 
 Get a commitment for a date to speak to the group. 
o Talk with the head of the organization and ask to be a speaker at a membership meeting 
2. Add information regarding your MTM program to your website. 
3. Utilize bag stuffers, buttons, and in-store posters to raise awareness of your MTM program. 
 
Reporting Requirements 
  
From March 1 to September 1 you are participating in this pilot program.  You will be in contact with Julie Hedlund and Brian Isetts 
on a monthly basis to discuss what is working, what’s not, what needs more support.  In order to facilitate these discussions, we ask 
that you document your experiences on a weekly basis. 
 
In between our monthly calls, if you feel you have an issue that needs more immediate attention, please feel free to contact us at 
the numbers below. 
 
Brian Isetts 651-301-1804 (c) 
Julie Hedlund 507-424-2802 (o), or 507-254-2056 (c) 
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Appendix E 
MEDICATION THERAPY MANAGEMENT SERVICES (MTMS) 
QUICK FACT SHEET 
 Description of Service:  
Medication therapy management describes contemporary models in which drug therapy decisions are coordinated collaboratively by 
physicians, pharmacists, and other health professionals together with the patient.[1]  MTMS, recognized in official CPT® health reporting 
nomenclature, encompasses a practice in which a pharmacist, working in collaboration with physicians and other care-givers, takes 
responsibility for all of a patient’s medication-related needs and is held accountable for this commitment.[2,3,4] During an initial MTMS 
encounter, the patient and pharmacist work together to assess all prescription and over-the-counter medications to ensure that the patient 
is achieving desired goals of therapy while avoiding or minimizing the adverse consequences of medication use.  
 Societal Need:  
The societal problem addressed by MTMS relates to drug-related morbidity and mortality ranging from adverse drug reactions and drug 
interactions to unsuccessful therapies and treatment failures. [4,5,6]  These drug therapy problems cost the United States healthcare 
system over $177 billion annually.[7]  It has been estimated that approximately 106,000 people die every year in the U.S. from these 
unfortunate medication consequences.[8] 
 Causes:  
Causes of drug therapy problems are due to system failures, rather than the fault of individuals. [9] Approximately 50-60% of drug therapy 
problems are preventable when there is a rational and consistent medication use system in place. [5,10,11,12] 
 Results:  
Pharmacists working in collaboration with physicians through redesigned medication use systems reduce drug-related morbidity and 
mortality. *13,14,15+  For every $1 invested in systems that integrate pharmacists’ services into medication therapy management, almost 
$17 is saved in total healthcare expenditures.[16]  In addition, the overall benefit to cost ratio for clinical pharmacy services and other 
MTMS has been estimated to be in excess of $23:1.[17]  
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